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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYSystemic and local signals must be integrated by mammary stem and progenitor cells to regulate their cyclic growth and turnover in the
adult gland. Here, we show RANK-positive luminal progenitors exhibiting WNT pathway activation are selectively expanded in the
human breast during the progesterone-high menstrual phase. To investigate underlying mechanisms, we examined mouse models
and found that loss of RANK prevents the proliferation of hormone receptor-negative luminal mammary progenitors and basal cells,
an accompanying loss of WNT activation, and, hence, a suppression of lobuloalveologenesis. We also show that R-spondin1 is depleted
in RANK-null progenitors, and that its exogenous administration rescues key aspects of RANK deficiency by reinstating a WNT response
andmammary cell expansion. Our findings point to a novel role of RANK in dictatingWNTresponsiveness tomediate hormone-induced
changes in the growth dynamics of adult mammary cells.INTRODUCTION
The terminal ductal lobular units in the adult humanmam-
mary gland and their lobuloalveoli counterparts in the
mouse are key hormone-sensitive structures (Cardiff and
Wellings, 1999). They are also foci of milk-secreting cells
following pregnancy and represent major sites of breast
cancer development in both species. Increased progester-
one levels that occur both during the reproductive cycle
and pregnancy trigger a dynamic growth response in these
structures, resulting in a documentedmarked expansion in
the number of stem and progenitor cells in the mammary
glands of mice (Asselin-Labat et al., 2010; Joshi et al.,
2010). These primitive cells lack estrogen and progesterone
receptors (ER–PR–) and thereforemust respond to these hor-
mones through indirect mechanisms via receipt of critical
signals from other types of cells within the mammary
stem cell niche that are ER+PR+ (Joshi et al., 2012). WNT
signaling is thought to contribute to the regulation of
stem cell self-renewal and differentiation responses in
many tissues (Nusse et al., 2008), including the mouse
mammary gland (van Amerongen et al., 2012; Zeng and
Nusse, 2010). However, the specific mechanisms that con-
trol the ability of mammary stem and progenitor cells to
respond to WNT ligands have remained largely undefined.
In this study, we show that the Receptor Activator of Nu-
clear factor Kappa B (RANK) ligand andWNT paracrine sig-
nals are conserved in adult mouse and human mammary
tissue and fluctuate similarly during the cyclic progenitor
expansion seen in both species. By exploiting a combina-tion of genetic and pharmacological approaches, we also
reveal an interaction between the RANK and WNT path-
ways that provides the molecular circuitry essential for
the WNT response and the expansion of ER–PR– mammary
progenitors in the adult mouse mammary gland.RESULTS
Luminal Progenitors Are Targeted by Progesterone in
the Adult Human Breast
We have previously reported that the progesterone-domi-
nant phase of the mouse estrous cycle is marked by an
increase in stem and progenitor cells, likely arising from
paracrine stimulation of ER–PR– primitive cells by RANKL
and WNT4 produced from adjacent ER+PR+ cells (Joshi
et al., 2010). To determine whether a similar mechanism
is operative in the human mammary gland, we analyzed
analogous subsets of mammary epithelial cells isolated
from reduction mammoplasty samples obtained from 63
normal premenopausal women at different stages of the
menstrual cycle (Figure 1A). Parallel sections of tissue
from each of these samples were classified as luteal-phase
(progesterone-high) or follicular-phase (progesterone-low)
according to previously published histologic criteria (Ram-
akrishnan et al., 2002). Phenotypic analyses, using es-
tablished marker sets (Eirew et al., 2008), showed that
the proportion of CD49f+EpCAM+ luminal progenitor-en-
riched cells was significantly higher in the luteal as
compared to the follicular phase, whereas the proportionStem Cell Reports j Vol. 5 j 31–44 j July 14, 2015 j ª2015 The Authors 31
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Figure 1. Increased Luminal Progenitors in the Progesterone-High Human Breast
(A) Schematic of the experimental procedure. Breast cells depleted of endothelial and hematopoietic cells are referred to as Lineage–
(Lin–).
(B) FACS profiles of human breast cell populations derived from morphologically categorized progesterone-high and -low breast tissue
samples: basal (CD49f+EpCAM/lo), luminal progenitor (CD49f+EpCAM+), mature luminal (CD49fEpCAM+), and stromal (CD49fEpCAM)
cell subsets.
(C) Quantification of basal, luminal progenitors, and mature cells in progesterone-high and -low human breast samples; data represent
mean ± SEM (n = 34 for progesterone-high, n = 29 for progesterone-low).
(D) Colony forming cell (CFC) frequency in FACS-purified basal and luminal progenitor subsets from P-high and P-low phases; data represent
mean ± SEM (n = 6 breast samples/phase).
(E) Ki67 and RANKL immunostaining in progesterone-high (P-high) and -low (P-low) tissue sections; scale bar, 50 mm.
(F) Quantification of Ki67 and RANKL positivity in P-high and -low tissues from E, measured as a ratio of Ki67 or RANKL positive pixel to
total pixel count within glandular regions; data represent mean ± SEM (n = 3 breast specimens/group).
(legend continued on next page)
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of CD49f+EpCAMlo/– basal cells was lower, and the propor-
tion of mature luminal cells remained unaffected by the
menstrual phase of the donor (Figures 1B and 1C).
In vitro colony-forming cell (CFC) assays performed on
these subsets from progesterone-high and -low samples
showed that even the frequencies of CFCs within both
the basal and luminal progenitor fractions were slightly
higher in the luteal phase samples (Figure 1D). Immuno-
staining of tissue sections prepared from these groups
showed abundant RANKL+ cells and increased numbers
of proliferating (Ki67+) cells in the luteal phase (Figures
1E and 1F). Taken together, these data suggest that
transient elevated progesterone levels induce a parallel
expansion of the luminal progenitor compartment in the
mammary glands of normal premenopausal women.
We also found levels of PR, RANK, RANKL, WNT4 tran-
scripts and the WNT downstream target TCF1 to vary in
expression between luteal and follicular phase samples of
purified human breast epithelial subpopulations (Fig-
ure 1G). PR expression was found to be the highest in the
mature luminal cell compartment and relatively lower in
the other fractions. RANKL, WNT4, and TCF1 were ex-
pressed in all three epithelial subsets, but RANKL and
WNT4 transcript levels were highest in the mature luminal
cells and further elevated in the luteal phase samples. In
contrast, TCF1 was elevated in the expanded luminal pro-
genitor subset in the luteal phase. RANK expression was
also detected in all epithelial subsets but at relatively higher
levels in the luminal progenitor-enriched fraction. This
pattern of gene expression is consistent with a mechanism
of progesterone effects on human mammary tissue being
mediated by a stimulation of mature PR-expressing cells
to produce RANKL, which then potentiates WNT respon-
sive luminal progenitors to induce their proliferation,
akin to the hormone-triggered mitogenic response previ-
ously identified in the mouse mammary gland.
RANK Signaling ExpandsMammary Epithelial Subsets
and Alveolar Progenitors
RANKL is a known, and sufficient, mediator of mammary
lobuloalveologenesis downstream of progesterone (Beleut
et al., 2010; Fata et al., 2000), but little is known of its effect
on different adult mammary epithelial subsets and progen-
itors. In contrast, WNT4 is known to be essential during
early phases of alveoli development in the mammary
gland, but is not sufficient for this process (Brisken et al.,
2000; Kim et al., 2009), although WNTs are accepted as(G) qRT-PCR for the indicated genes on FACS-purified subsets from
transcript levels plotted relative to the P-high group; data represent
respectively, except for PR where n = 4 per group).
Statistical significance is indicated as *p < 0.05, **p < 0.01, ***p <important stem cell growth factors (Nusse et al., 2008;
Zeng and Nusse, 2010). We therefore designed a series of
experiments in mice to investigate the role of RANK
signaling in mediating progesterone-driven changes in
distinct mammary epithelial subsets, and whether this
involved activation of a WNT response. Accordingly, we
compared the mitogenic response of mammary cells in
adult keratin 5 (K5)-Cre Rankfl/fl (RANK null) to control
Rankfl/fl ovariectomized mice treated with 17b-estradiol
alone (E) or with progesterone (EP) (Figure 2A). Mammary
cell preparations were depleted of hematopoietic and
endothelial cells during flow cytometry, and the resulting
lineage– (Lin–) population was analyzed using CD49f
and CD24 cell-surface markers (Stingl et al., 2006) to iden-
tify the luminal (CD24+CD49flo), basal (CD24+CD49fhi)
epithelial, and stromal (CD24–CD49f–) subsets (gating #1
in Figure 2A). The luminal CD24+CD49flo subset was
further segregated (gating #2) into CD24+CD49floCD61+
luminal progenitors (hereafter CD61+), and CD24+
CD49floCD61– luminal cells (hereafter CD61–), which in-
cludes mature cells and progenitors (Asselin-Labat et al.,
2007). To discern ER+PR+ and ER–PR– luminal epithelial
subsets, the luminal subset was also refined based on
Sca1 and CD49b markers (gating #3) into ‘‘ER+PR+’’
CD24+CD49floSca1+CD49b– non-clonogenic luminal cells
(hereafter NCL), ‘‘ER+PR+’’ CD24+CD49floSca1+CD49b+
progenitors (hereafter Sca1+) and ‘‘ER–PR–‘‘ CD24+CD49flo
Sca1–CD49b+ progenitors (hereafter Sca1–) (Shehata et al.,
2012). The latter, ER–PR– luminal cells have a high clono-
genic capacity and are considered enriched for alveolar pro-
genitors due to their significant levels ofmilk protein genes
(Shehata et al., 2012; Sleeman et al., 2007). These gating
strategies were used to comprehend the phenotypic and
functional defects arising from Rank deficiency across the
spectrum of cell compartments and progenitors reported
to date. Co-staining for CD61 together with Sca1 and
CD49b markers showed that the CD61+/– and Sca1+/– sub-
populations within the luminal compartment do not
entirely overlap such that Sca1– cells are found in both
the CD61+ and CD61– luminal cell fractions, whereas
CD61 cells are dispersed between the Sca1+ and Sca1
fractions (Figures S1A and S1B). PCR on genomic DNA
extracted from fluorescence-activated cell sorting (FACS)-
purified CD24+CD49fhi stem cell-enriched basal cells and
CD24+CD49flo luminal cell populations of K5-Cre Rankfl/fl
mammary glands showed that Rank is efficiently
deleted from both of these mammary cell compartmentsreduction mammoplasty samples shown in (B); GAPDH normalized
mean ± SEM (n = 6 and n = 7 breast samples for P-low and P-high,
0.0001.
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Figure 2. RANK Is Required for Progesterone-Induced Expansion of Mouse Mammary Epithelial Subsets and Alveolar Progenitor
Activity
(A) Schema of the experimental procedure; 17b-estradiol (E), 17b-estradiol + progesterone (EP), Lineage (Lin) i.e., cells depleted of
endothelial and hematopoietic cells, non-clonogenic luminal (NCL) cells, estrogen receptor (ER), and progesterone receptor (PR).
(B) Whole-mount (WM; scale bar, 100 mm) and Ki67 immunostaining (scale bar, 20 mm) of control and K5-Cre Rankfl/fl mammary glands
following EP treatment.
(C) Quantification of Ki67+ proliferating cells in Rank-null and control glands; data represent mean ± SEM (n = 3 mice/group).
(D) FACS profiles of luminal (CD24+CD49flo), basal (CD24+CD49fhi), and stromal (CD24CD49f) mammary cell subpopulations in ovari-
ectomized control and K5-Cre Rankfl/fl mice following treatment with E or EP (gating #1).
(E) Representative FACS plots of basal, CD61+ luminal, and CD61 luminal cell populations within CD24+ mammary epithelial cells
(gating #2).
(F) Proportions of NCL cells (hormone receptor-positive), Sca1+ (hormone receptor-positive) progenitors, and Sca1 (hormone receptor-
negative) alveolar progenitors in the luminal population of EP-treated control and K5-Cre Rankfl/fl mice (gating #3).
(G–K) Quantification of (G) luminal (L), basal (B), and stromal (S) cell subsets from (D), (H) indicated cell populations in (E), and (I)
luminal cell populations in (F); data represent mean ± SEM of n = 3 mice/group for (G) and (H) and n = 4 mice/group for (I). Colony forming
cell capacity of FACS-sorted (J) basal and CD61+, CD61 luminal progenitors, (K) Sca1+ and Sca1 progenitors, on fibroblast feeders in vitro
from EP-stimulated control and K5-Cre Rankfl/fl mice; data represent mean ± SEM of n = 3 mice/group for (J) and (K).
(legend continued on next page)
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(Figure S1C). K5 is a basal cell marker in the adult mam-
mary gland, but an absence of Rank in the luminal cells
of the adult mammary gland is not surprising since these
arise during early development frommultipotent K5+ basal
cells (Van Keymeulen et al., 2011). We observed that
administration of progesterone to K5-Cre Rankfl/fl mice
failed to stimulate development of mammary alveoli and
the glands of thesemice containedmarkedly fewer prolifer-
ating cells than Rankfl/fl controls (Figures 2B and 2C),
although they retained normal basal- and luminal-
restricted patterns of cytokeratin and PR expression (Fig-
ure S2A). Importantly, K5-Cre Rankfl/fl mice did not exhibit
the progesterone-stimulated expansion of basal and
luminal epithelial subsets, characteristic of control mice
(Figures 2D–2I). The stromal cell population did not appear
altered in the absence of RANK. In the luminal subsets,
CD61 cells were significantly reduced and the number
of Sca1 progenitors in EP-treated K5-Cre Rankfl/fl mice
was 3-fold lower than in controls (Figures 2E, 2F, 2H, and
2I). In contrast, the number of Sca1+ cells in the same
glands remained similar to controls.
We then performed functional assays to examine
whether Rank loss affects progenitor activity. A previous
study reported an increase in the relative numbers of basal
and luminal cells and a decline in CD61+ luminal cells in
Rank overexpressingmice (Pellegrini et al., 2013). However,
we found that the loss of Rank did not significantly alter the
total numbers of CD61+ luminal cells or their CFC content
(Figures 2H and 2J). In contrast, the CFC frequencies in
FACS-purified CD61 cells (Figure 2J) and ERPR, Sca1
(Figure 2K) luminal cells were significantly lower than in
controls, whereas the CFC frequency in basal or ER+PR+
Sca1+ cells was not significantly altered. This suggests that
RANK signaling acts primarily by instructing ERPR
alveolar progenitors contained within the Sca1 and
CD61 luminal subsets. In vivo limiting dilution trans-
plantation experiments onmammary cells from ovariecto-
mized EP-treated K5-Cre Rankfl/fl mice further showed that
the frequency of mammary stem cells (able to produce a
macroscopic ductal outgrowth in a pre-cleared mammary
fat pad) was comparable to control cells (Figures 2L and
2M). In contrast, the capacity of Rank-deficient cells to
generate alveoli was severely compromised (Figures 2L
and 2M; Table S1). Thus, RANK is critical for ensuring the
activity and repopulation capacity of adult mouse mam-
mary epithelial progenitors that normally generate alveoli.(L) Representative images of ductal and alveolar-containing outgrow
control donor mice injected into fat pads of subsequently impregnat
(M) Gland repopulation rates in limiting dilution assays in vivo scored
frequency (MRU freq). Data are pooled from at least two independen
process; control cells: p = 0.81 (ductal and alveolar), K5-Cre Rankfl/fl
*p < 0.05, **p < 0.01. See also Figure S1 and Table S1.The Adult Mammary Epithelial WNT Response Is
Dependent on RANK Signaling
Next, we determined whether and how an absence of
RANK affects the adult mammary WNT response (Figures
3A–3E). qRT-PCR measurements on FACS-purified cells
showed that the progesterone-mediated induction of
Wnt4 ligand in the luminal compartment still occurred in
K5-Cre Rankfl/fl mice, whereWnt4 was specifically detected
in the CD61 luminal cells that also express high levels of
Rankl (Figure 3A). Rank expression was absent, as expected,
in K5-Cre Rankfl/fl mice and expression of Rankl appeared
reduced in CD61 cells from these mice (Figure 3A). How-
ever, immunostaining revealed a comparable number of
RANKL-positive cells to be detectable (Figures 3C and
3D). Transcript levels for the cell-cycle activators Cyclin
D1 and Cyclin D2 were significantly decreased in CD61
luminal cells and basal cells, respectively, of RANK-defi-
cient glands (Figure S2B) consistent with their lack of a
progesterone-stimulated proliferative response. Rank-null
CD61 luminal cells also had significantly reduced expres-
sion of themilk protein, b-casein, in comparison to controls
(Figure S2B), consistent with the compromised develop-
ment of functional lobuloalveoli in Rank-deficient glands.
Recently, CXCR4, the receptor for CXCL12, was shown to
be important for mammary progenitor cell fate (Shiah
et al., 2015) and we found its expression to be also
decreased in the Rank-deficient Sca1 luminal progenitor
population, although this effect did not reach statistical
significance (Figure S2C). ELF5 is a transcription factor
that dictates alveolar development, and its expression has
been reported to be decreased in CD61 and CD61+
luminal cells following the loss of Rank (Lee et al., 2013).
Measurement of Elf5 mRNA levels within the Sca1
luminal progenitor fraction showed no overt changes in
the absence of Rank (Figure S2C). STAT5A is another tran-
scription factor that regulates alveologenesis (Liu et al.,
1997), and we found its expression in Sca1 progenitors
of Rank-deficient mice to be reduced (Figure S2C).
Since progesterone has been shown previously to upre-
gulate the expression of the WNT co-receptor, Lrp5, and
theWNT target, Tcf1, in both luminal and basal mammary
cells (Joshi et al., 2010), we also examined the expression of
these elements in progesterone-stimulated K5-Cre Rankfl/fl
purified mammary cells. Remarkably, there was no
induction in the expression of Lrp5, Lrp6, or Tcf1 in either
the luminal or basal mammary subpopulations ofths from 5,000 mammary cells of EP-stimulated K5-Cre Rankfl/fl and
ed recipients (scale bar, 500 mm).
for either ductal or alveolar outgrowths; mammary repopulating unit
t experiments for each group and are consistent with a single-hit
cells: p = 0.96 (ductal) and p = 0.13 (alveolar).
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Figure 3. Progesterone-Triggered WNT Responsiveness Is Dependent on RANK Signaling
(A) Expression of RANKL and WNT pathway components measured by qRT-PCR relative to b-actin in FACS-purified CD61, CD61+ luminal,
and CD49fhi basal epithelial subpopulations from control and K5-Cre Rankfl/fl mice stimulated with 17b-estradiol and progesterone (EP).
Expression was normalized to b-actin levels and plotted relative to that of CD49fhi basal cells from controls, set at 1. Data represent mean ±
SEM; (n = 3 mice for each group).
(B) Pr expression status of FACS-sorted basal (B), non-clonogenic luminal (NCL), Sca1+, Sca1 luminal cells, and Keratin, Rank, Wnt
signaling gene expression in the latter hormone receptor-negative alveolar progenitor population, from control and Rank-null mice in
response to EP; b-actin-normalized transcript levels are shown plotted relative to control NCL cells for Pr, and control Sca1 cells for the
other genes. Data represent mean ± SEM of n = 3 mice/cell fraction/group.
(C) Immunostaining of RANKL and WNT target, TCF1, in paraffin-embedded K5-Cre Rankfl/fl and control mammary tissue sections;
scale bar, 20 mm.
(legend continued on next page)
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EP-stimulated K5-Cre Rankfl/fl mice (Figure 3A), and all
three genes, as well as the Axin2 target gene, were also
markedly reduced in the ERPR, Sca1 luminal progeni-
tors isolated by FACS from K5-Cre Rankfl/fl glands by com-
parison to controls (Figure 3B). Moreover, these Sca1 cells
in the luminal compartment that co-express luminal and
basal keratins are considered bipotent (Shehata et al.,
2012) and showed a lower level of K14 expression (a basal
marker) without an alteration in K18 (a luminal marker)
in Rank-null mice (Figure 3B). This suggests that RANK
may help to promote the retention of basal characteristics
in luminal cells. Immunostaining of mammary tissue
from progesterone-treated K5-Cre Rankfl/fl mice showed
that TCF1+ cells remained scarce in contrast to the promi-
nent numbers of TCF1+ cells in similarly treated control
mammary tissue (Figures 3C and 3D). Immunostaining
for AXIN2, a key WNT target gene, also demonstrated a
lack of AXIN2-expressing cells in the RANK-deficient mam-
mary gland compared to their increased abundance
following progesterone stimulation in controls (Figure 3E).
This complete lack of expression of key WNT signaling
components points to a role for RANK in controlling the
molecularmachinery that generatesWNT-responsive adult
mammary cells when progesterone levels increase. It has
been reported that Wnt4-deficient mammary glands lack
early lobuloalveolar development during pregnancy
(Brisken et al., 2000), and that transgenicWnt4 expression
is not sufficient to generate this morphogenetic program
(Kim et al., 2009), whereas RANKL signaling is (Fernan-
dez-Valdivia et al., 2009). Our findings here explain these
previous observations since we demonstrate that, despite
Wnt4 ligand expression, RANKL-RANK signaling is essen-
tial to establish the WNT response in progenitor cell-
enriched epithelial compartments.
RANK Signaling Activates WNT-Responsive ERPR
Subsets of Mammary Epithelial Cells
We next utilized Axin2-LacZWNT reporter mice to investi-
gate whether and how RANK signaling might affect the dy-
namics ofWNT-responsive cell populations. These reporter
mice express lacZ through the endogenous promoter of
Axin2, a WNT/b-catenin target gene (Zeng and Nusse,
2010). Ovariectomized EP-treated Axin2-LacZ mice were
co-administered theRANKL inhibitor, RANK-Fc (Figure 4A).
As seen using our genetic approach to delete Rank, mice
treated with RANK-Fc exhibited a blunted progesterone-
induced expansion of both the luminal (CD24+CD49flo)(D) Quantification of RANKL and TCF1 protein levels in mammary tissue
total pixel count, averaged from ten glandular regions per mouse ma
(E) Immunofluorescent detection of AXIN2-expressing cells (green; w
response to 17b-estradiol (E) and EP; scale bar, 30 mm.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.and basal (CD24+CD49fhi) populations, and also sup-
pressed lobuloalveologenesis (Figures 4B–4D). Previous
studies using WNT reporter mice have documented the
presence of WNT-responsive cells (5%) within basal, but
not luminal cells, of adult virgin mice (van Amerongen
et al., 2012; Zeng and Nusse, 2010). During pregnancy,
however, lineage tracing experiments have identified
WNT-responsive luminal cells adjacent to basal cells within
alveolar structures, suggesting their origin from a common
bipotent progenitor (van Amerongen et al., 2012). Inmam-
mary tissue from EP-stimulated WNT reporter mice, we
detected Axin2-LacZ+ cells by immunostaining in the
basal layer and in luminal cells, including those that are
PR (Figure 4E). Abundance of these cells was decreased
following RANK-Fc treatment (Figure 4E). Using flow
cytometry, we observed a small AXIN2+ WNT-responsive
population in the basal fraction and negligible numbers
in luminal subsets of the adult virgin mammary gland
compared to LacZ– controls (Figure 4F), consistent with
previous reports. AXIN2+ cell numbers were found to be
greatly elevated in ovariectomized EP-treated mice, pre-
dominantly existing within ER–PR–, basal (50%) and
Sca1– luminal subsets (12%) (Figure 4F). RANK-Fc treat-
ment of these mice resulted in a marked depletion of
WNT-responsive AXIN2+ cells in both the basal and Sca1–
luminal fractions (Figures 4F and 4G). Together, these re-
sults reveal that RANK signaling selectively amplifies hor-
mone receptor-negative, WNT-responsive basal cell and
luminal progenitor numbers in response to progesterone.
R-SPONDIN1 Is a Key Mediator of the RANK-Induced
Activation of WNT Responsiveness
Given the role of R-SPONDIN1 (RSPO1) as a potent WNT
signal enhancer and stem cell renewal factor (de Lau
et al., 2014), we next interrogated whether RSPO1 is altered
when RANK signaling is prevented. In purified cell frac-
tions from EP-stimulated mice, we observed Rspo1 to be
highly expressed in control Sca1 luminal progenitor cells
similar to a previous report (Cai et al., 2014). However, its
expression was severely impaired in Sca1 cells derived
from K5-Cre Rankfl/fl mice (Figure 5A). To determine
whether RSPO1 is a key downstream mediator of RANK
effects on mammary progenitors, fat pads of EP-treated
K5-Cre Rankfl/fl mice were injected once with recombinant
RSPO1 or vehicle, 3 days prior to their analysis (Figure 5B).
RSPO1 injection resulted in the formation of structures
reminiscent of alveoli in Rank-nullmammary glands, albeits shown in (C), measured as a ratio of RANKL or TCF1 positive pixel to
mmary gland specimen; data are mean ± SEM (n = 3 mice/group).
hite arrowheads) in control and Rank-deficient mammary glands in
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(legend continued on next page)
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not as uniformly as in controls, suggesting that other
factors downstream of RANK likely cooperate with RSPO1
to maximize alveolar differentiation (Figure 5C). At the
cellular level, RSPO1 led to a robust rescue in the expansion
of basal, total luminal cells, and Sca1 progenitor cell
numbers that were typically defective in the Rank-null
mammary gland (Figures 5D and 5E). The functional clo-
nogenic capacity of Rank-null basal cells and Sca1 cells
alsomodestly increased following in vivo RSPO1 treatment
(Figure 5F). Of note, the WNT response, as determined by
AXIN2 immunostaining, was restored in luminal and basal
cells of Rank-deficient mammary tissue following RSPO1
rescue (Figure 5G). These data collectively uncover RSPO1
as a central executor of RANK signaling effects on epithelial
progenitors and the WNT response in the adult mammary
gland.DISCUSSION
In this study, we provide evidence that human breast
luminal progenitors undergo a similar type of progester-
one-mediated expansion of their numbers during the luteal
phase of the menstrual cycle as previously documented in
the mouse (Asselin-Labat et al., 2010; Joshi et al., 2010).
This cyclical rise in luminal progenitor numbers would be
anticipated to pose repeated opportunities for mutagenic
events to accumulate, and thus offer an explanation for
an increasing risk of breast cancer with more menstrual cy-
cles (Kelsey et al., 1993). Luminal progenitors have been
implicated as the cell of origin in BRCA1-related breast can-
cers (Lim et al., 2009; Molyneux et al., 2010), and in more
recent work we have shown that these cells possess short
dysfunctional telomeres and higher levels of reactive oxy-
gen species, consistent with a higher propensity for trans-
formation (Kannan et al., 2013, 2014). Previous studies
investigating the effects of progesterone on human mam-
mary cells have relied on progestin treatment of cultured
human breast cells or organoids (Graham et al., 2009;
Tanos et al., 2013). In a recent study, ex vivo progestin
treatment of human mammary epithelial organoids or mi-(D) Histogram of total Lin cells in the luminal (L), basal (B), and stro
(EP), n = 6 (EP+RANK-Fc) mice.
(E) Immunofluorescent images of mammary tissues from mice stimu
DAPI+ nuclei; blue (top) and co-stained for progesterone receptor (
Axin2-LacZ+ cells within the PR luminal compartment and arrowhead
scale bar, 25 mm.
(F) FACS analysis of Axin2-Lacz+ WNT-responsive cells in B, L and segre
row 1), and Axin2-LacZ/+ WNT reporter adult virgin mice untreated (
(G) Quantification of the total numbers of AXIN2+ cells in B, L, Sca1+
represent mean ± SEM of n = 3 mice/cell fraction/group.
*p < 0.05, **p < 0.05, ***p < 0.0001.crostructures did not shift the distribution of epithelial
subpopulations, although increased RANKL was observed
(Tanos et al., 2013). The significant differences that we
observed may reflect the fact that the cells we analyzed
were obtained directly from tissues removed from women
in progesterone-high and progesterone-low menstrual
phases, thus pointing to the potential importance of avoid-
ing in vitro treatments that may not faithfully recapitulate
conditions operative in vivo. Our data also provide a snap-
shot of RANKL and WNT activity during the luteal phase
in the human breast, thus indicating their involvement
in mediating the physiological changes in circulating
progesterone levels on the human luminal progenitor
compartment.
WNTsignaling is well recognized for its role in regulating
stem and progenitor cells in diverse systems (Nusse et al.,
2008). Elevated levels of b-catenin, indicative of aberrant
WNT signaling, are reported in more than 50% of human
breast carcinomas, correlate with poor prognosis, and are
preferentially found in the aggressive triple-negative
(ERPRHER2) basal-like subtype (Geyer et al., 2011; Lin
et al., 2000; Ryo et al., 2001). RANK signaling is also
emerging as a significant variable in breast cancer (Schra-
mek et al., 2010) withmicroarray data showing the highest
levels of RANK in poor prognosis basal-like human breast
cancers in comparison to other molecularly defined
subtypes (Santini et al., 2011). Progesterone is likewise
becoming increasingly recognized as a critical contributor
to human breast cancer development, largely through
lessons learned from increased breast cancer incidence in
hormone replacement therapy trials with progestin combi-
nations (Beral, 2003; Chlebowski et al., 2015; Joshi et al.,
2015; Rossouw et al., 2002). A recent study also reported
significantly higher levels of progesterone in BRCA1/2
mutation carriers who are at increased risk of ovarian and
breast cancer, suggesting a progesterone influence on pre-
menopausal breast cancer risk (Widschwendter et al.,
2013).
RANKL andWNT signaling are known to be downstream
effectors of progesterone (Beleut et al., 2010; Brisken et al.,
2000; Fata et al., 2000; Joshi et al., 2010; Rajaram et al.,mal (S) cell fractions. Data represent mean ± SEM of n = 4 (E), n = 5
lated with EP ± RANK-Fc stained for Axin2-LacZ (b-gal); magenta,
PR); green, keratin14 (K14); red (bottom). White arrows indicate
s point to Axin2-LacZ+ cells within the K14+PR basal compartment;
gated Sca1+ and Sca1 luminal cell populations of Axin2+/+ (LacZ–;
row 2) and treated with EP ± RANK-Fc (rows 3 and 4).
, and Sca1 epithelial subsets in EP ± RANK-Fc treated mice; data
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Figure 5. RSPO1 Rescues the Expansion of Mammary Epithelial Subsets, Progenitors, and the WNT Response in the Absence of
RANK Signaling
(A) R-spondin1 (Rspo1) expression in the basal and luminal (NCL, Sca1+, Sca1) mammary epithelial subsets of EP-treated control
and K5-Cre Rankfl/fl mice. b-actin-normalized transcript levels are plotted relative to control Sca1 cells; data represent mean ± SEM of
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(B) Schema of the RSPO1 rescue experimental procedure.
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(legend continued on next page)
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Figure 6. Model Illustrating the Impact of RANK Signaling on
WNT-Responsive Mammary Progenitors
Progesterone (P)-triggered RANKL-RANK paracrine signaling
within the mammary stem cell niche stimulates the expression of
R-SPONDIN1 (RSPO1) from the hormone-receptor negative (ERPR)
luminal alveolar progenitor compartment (Sca1), potentiating the
WNT response and amplifying the numbers of ERPR luminal pro-
genitors andbasal cells. ERPR luminal alveolar progenitors express
basal markers such as K14 and are considered bipotent, likely
contributing to the basal lineage within alveolar structures, while
basal WNT-responsive cells may continue to replenish the luminal
progenitor pool. Together, these cellular events converge to generate
lobuloalveolar units in the adult progesterone-exposed gland.2015), but their underlying mechanism of action on
distinct cellular targets in the normal and neoplastic mam-
mary gland remains poorly understood. We now demon-
strate that RANKL from ER+PR+ luminal epithelial cells
acts on the mouse ER–PR– luminal alveolar progenitor
compartment to activate RSPO1 and enable WNT respon-
siveness, resulting in the expansion of ERPR luminal
alveolar progenitors and basal cells that jointly culminate
in the generation of lobuloalveoli (Figure 6). Interestingly,
RSPO1 has been shown to be required for alveolar forma-
tion in the mouse mammary gland, where its expression
pattern during gestation paralleled that of Wnt4 (Chadi
et al., 2009). RSPO1 enhances WNT signaling through its
stabilizing effects on the WNT receptor complex and pro-
motes the expansion of intestinal LGR5+ stem cells (de
Lau et al., 2014). Recent work also shows its cooperation
with WNT4 for mammary stem cell renewal (Cai et al.,
2014). Here, we discover a crucial role for RANKL in
inducing RSPO1 and engaging the WNT response in prim-
itive mammary cells, thus enabling them to respond to
progesterone. Given the widely documented role of WNT
signals in controlling stem and progenitor cells in other
tissues, our findings may prove to have broader relevance.(G) Immunofluorescent staining of mammary tissues from contro
AXIN2 (green), DAPI (blue), Keratin 14 (K14; magenta), and Kera
cells in the luminal compartment, and white arrowheads point to WN
0.05, **p < 0.01.The RANKL-RANK driven, WNT-responsive ERPR
luminal progenitors in the mouse and RANK-expressing
luminal progenitors that expand in the human breast dur-
ing the progesterone-high menstrual phase appear to
represent analogous, highly proliferative progenitors
within lobuloalveolar units. Since lobuloalveoli are the
most common site of mammary cancer development in
both mouse and human, it is tempting to nominate this
progenitor as a strong candidate for breast carcinogenesis.
Targeting RANK signaling in clinical trials utilizing Deno-
sumab, a fully human monoclonal antibody to RANKL,
has proved effective in reducing skeletal-related events
and bone metastasis in breast cancer patients (Stopeck
et al., 2010). Thus, it may be important to test the thera-
peutic capacity of Denosumab against primary breast
cancer for treatment or prevention. However, in light of
breast cancer heterogeneity and emerging RANK expres-
sion data, variable effects on different breast cancer
subtypes and stages would also be anticipated to affect
therapeutic outcomes. Since the WNT pathway is consid-
ered therapeutically elusive, RANK signaling blockade
may also serve as a means to curtail WNT activity during
breast pathogenesis.EXPERIMENTAL PROCEDURES
Mice
Rankflox mice and K5-Cre Rankfl/fl knockout mice have been
described previously (Schramek et al., 2010) and were maintained
on a pureC57BL/6 background. Cre-mediated deletion is described
in the Supplemental Experimental Procedures.Wild-typemice and
Axin2-LacZ/+ (Stock #009120) mice were purchased from the Jack-
son Laboratory. All mice were cared for according to the Canadian
Council for Animal Care guidelines under protocols approved by
the Animal Care Committee of the Ontario Cancer Institute,
Toronto, Ontario.
Ovariectomy and Treatments
K5-Cre Rankfl/fl, Rankfl/fl controls and wild-type mice (10–13 weeks
old) were bilaterally ovariectomized and allowed to recover for
1 week. Mice were subcutaneously implanted with 14-day slow
release pellets (Innovative Research of America) of 17b-estradiol
(E, 0.14 mg) or 17b-estradiol + progesterone (EP, 0.14 mg E +
14mg P). For RANKL inhibition, RANK-Fc (kindly provided byWil-
liam Dougall, Amgen) was injected subcutaneously (10 mg/kg
RANK-Fc or PBS; three times/week) over the 14-day period. For
Rank knockout rescue experiments, R-SPONDIN1 (R&D Systems)
or PBS + 0.1%BSA (vehicle) alone was injected into the mammary
fat pad (5 mg/gland) following 11 days of EP treatment.l and K5-Cre Rankfl/fl mice treated with vehicle or RSPO1 for
tin 18 (K18; red); white arrows indicate AXIN2+ WNT-responsive
T-responsive cells found in the basal layer; scale bar, 25 mm.*p <
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Whole-Mount, Immunostaining, RNA Isolation, and
Real-Time PCR Analysis
Please see Supplemental Experimental Procedures for detail
description.
Mammary Cell Preparation and Flow Cytometry
Singlemammary cell suspensions were generated from each pair of
fourth inguinal mammary glands from individual mice by enzy-
matic digestion and flow cytometry performed as reported (Joshi
et al., 2010) and described in Supplemental Experimental Proce-
dures. To analyze b-galactosidase activity andWNT-responsive cells
in Axin2-LacZ/+mice, a fluorogenic b-galactosidase substrate (FDG)
with the FluoReporter lacZ Flow Cytometry kit (Molecular Probes)
was used according to the manufacturer’s protocol. FACS analysis
wasperformedusingFACSCaliburor FACSCanto II (BDBiosciences)
and FlowJo software (Tree Star). Gating was defined based on single
color, isotype, and fluorescence minus one negative controls. Cell
sorting was performed on a FACSAria (BD Biosciences). The purity
of sortedpopulationswas routinely >95%.Histologically confirmed
normal, anonymized discard breast tissue samples from 63 non-
lactating, premenopausal women (17–50 years) undergoing reduc-
tion mammoplasties for indications other than neoplasia were
obtainedwith informed consent according to procedures approved
by the University of British Columbia Research Ethics Board. Their
menstrual phase-specificmorphologywas identified as defined pre-
viously (Ramakrishnan et al., 2002). Viable single cell suspensions
were prepared from previously isolated and cryopreserved organo-
ids as previously described (Eirew et al., 2008). The cells were then
labeled with fluorochrome-conjugated antibodies CD31 (Bio-
Legend, cat. #303118), CD45 (BioLegend; cat. #304016) for endo-
thelial and hematopoietic cell exclusion, respectively; CD49f (BD
Biosciences; cat. #555735) and EpCAM (BioLegend; cat. #324206)
formammarycells;DAPI forcell viability in subpopulationdistribu-
tion analysis by flow cytometry or to enable highly purified subsets
to be isolated by FACS (>95%) using either an Influx-II or FACSAria
(Becton Dickinson) (Eirew et al., 2008).
CFC Assays and In Vivo Limiting Dilution Assays
In vitro 2D CFC assays were performed as reported (Kannan et al.,
2013; Makarem et al., 2013; Stingl et al., 2006). Limiting dilution
transplantation assays of total mammary cells were performed to
determine ductal and alveolar outgrowth rates in vivo. Details
can be found in Supplemental Experimental Procedures.
Statistical Analysis
Values are reported as mean ± SEM comparison of data between
multiple groups was performed using one-way ANOVA followed
by Tukey’s post hoc multiple comparison test, and analysis be-
tween two specific groups was made using Student’s t test. Statisti-
cal significance is recognized at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
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